This HTML5 document contains 40 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n8http://linked.opendata.cz/resource/drugbank/drug/DB05855/identifier/chemspider/
n6http://bio2rdf.org/drugbank:
n12http://linked.opendata.cz/resource/drugbank/drug/DB05855/identifier/wikipedia/
admshttp://www.w3.org/ns/adms#
n10http://linked.opendata.cz/resource/drugbank/drug/DB05855/identifier/bindingdb/
n11http://linked.opendata.cz/resource/drugbank/drug/DB05855/identifier/pubchem-compound/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
n9http://linked.opendata.cz/resource/drugbank/drug/DB05855/identifier/drugbank/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB05855
rdf:type
n3:Drug
n3:description
Rivanicline (TC-2403, RJR-2403, (E)-metanicotine) is a drug which acts as a partial agonist at neural nicotinic acetylcholine receptors. It is subtype-selective, binding primarily to the α4β2 subtype. It has nootropic effects and was originally developed as a potential treatment for Alzheimer's disease, but a second action that was subsequently found was that it inhibits the production of Interleukin-8 and thus produces an antiinflammatory effect, and so it has also been developed as a potential treatment for ulcerative colitis. Rivanicline also has stimulant and analgesic actions which are thought to be mediated through stimulation of noradrenaline release, and so it could potentially also have other applications.
n3:generalReferences
# Spoettl T, Paetzel C, Herfarth H, Bencherif M, Schoelmerich J, Greinwald R, Gatto GJ, Rogler G: (E)-metanicotine hemigalactarate (TC-2403-12) inhibits IL-8 production in cells of the inflamed mucosa. Int J Colorectal Dis. 2007 Mar;22(3):303-12. Epub 2006 May 20. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16715250 # Jang J, Sin KS, Park H: Synthesis of (+/-)-methyl-(1-aryl-4-pyridin-3-yl-but-3-enyl)-amines. Arch Pharm Res. 2001 Dec;24(6):503-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11794523 # Sapronov NS, Fedotova YO, Kuznetsova NN: Antiamnestic effect of alpha7-nicotinic receptor agonist RJR-2403 in middle-aged ovariectomized rats with Alzheimer type dementia. Bull Exp Biol Med. 2006 Dec;142(6):700-2. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17603674 # Li X, Eisenach JC: Nicotinic acetylcholine receptor regulation of spinal norepinephrine release. Anesthesiology. 2002 Jun;96(6):1450-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12170059
n3:group
investigational
n3:indication
Investigated for use/treatment in ulcerative colitis.
owl:sameAs
n6:DB05855
dcterms:title
Rivanicline
adms:identifier
n8:4470511 n9:DB05855 n10:50061561 n11:5310967 n12:Rivanicline
n3:mechanismOfAction
Rivanicline is a (E)-metanicotine hemigalactarate. It effectively inhibits TNF- and LPS-induced IL-8 production in different cell types.
n3:synonym
(E)-N-Methyl-4-(3-pyridinyl)-3-butene-1-amine
n3:IUPAC-Name
n4:271B47C9-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B47CF-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B47CE-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B47CB-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B47CC-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B47CD-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B47C7-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B47C8-363D-11E5-9242-09173F13E4C5 n4:271B47C5-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B47C6-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B47D5-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B47D6-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B47D0-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B47D1-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B47D3-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B47D2-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B47D4-363D-11E5-9242-09173F13E4C5
n3:casRegistryNumber
538-79-4
n3:Bioavailability
n4:271B47DA-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B47DC-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B47DD-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B47D9-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B47D8-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B47DB-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B47CA-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B47D7-363D-11E5-9242-09173F13E4C5